Latest Administration News

Neuren Pharmaceuticals has secured a pivotal FDA Type C Meeting to discuss primary efficacy endpoints for its Phase 3 trial of NNZ-2591 targeting Phelan-McDermid syndrome, advancing its rare disease drug development.

Blackstone Minerals is set to merge with IDM International, combining expertise and local presence to advance exploration of the world-class Mankayan copper-gold porphyry project in the Philippines.

Loyal Lithium unveils a strategic pivot to broaden its North American lithium and battery technology portfolio, leveraging new US energy policies and $5.5 million in funding to capitalize on the continent’s evolving energy grid demands.

Podium Minerals has completed its acquisition of EV Nickel’s assets, consolidating key nickel and PGM projects and welcoming industry giant Johnson Matthey as a 16.25% shareholder.

InFocus Group Holdings has completed its acquisition of Bangkok-based Prodigy9, enhancing its software engineering and data analytics capabilities while aiming for rapid cash flow generation.

A new peer-reviewed study highlights Cynata Therapeutics’ Cymerus™ iPSC-derived MSCs as superior to traditional donor tissue-derived MSCs in potency, consistency, and regenerative potential.

A1 Investments & Resources Ltd reported a modest cash outflow for the December quarter while actively pursuing acquisition opportunities backed by secured funding. The company aims to finalize a deal soon, contingent on shareholder and regulatory approvals.

Wellnex Life has secured Therapeutic Goods Administration approval for its Liquid Paracetamol plus Caffeine Soft Gel, marking its fourth market authorisation and opening new revenue avenues.

Aeris Environmental has updated its quarterly cash flow report, confirming ongoing operational cash outflows but expressing confidence in maintaining current cash flow levels while exploring new funding avenues.

VanEck Investments Limited has announced final dividends for a suite of its Australian and global bond ETFs, reaffirming steady income streams for investors ahead of February payments.

Janus Henderson Investors has announced the final distribution for its Sustainable Credit Active ETF, delivering 18.3819 cents per unit for January 2025. Key dates for investors include the ex-date on 3 February and payment on 13 February.

Alterity Therapeutics has raised over A$2 million through its U.S. ATM facility and expects nearly A$5.7 million in Australian tax rebates, fueling the advancement of its lead neurodegenerative drug candidate ATH434 following promising Phase 2 results.